Boehringer
Lilly and Boehringer’s Jardiance reduces hospitalisation and CV death risk from heart failure at Phase 3
July 30, 2020Research and Development Boehringer, Eli Lilly, jardiance, pharma
Boehringer Ingelheim and Eli Lilly have announced strong Phase 3 news on their sodium-glucose co-transporter-2 (SGLT2) inhibitor Jardiance (empagliflozin) in …
Boehringer withdraws its £700m investment in Hikma Pharmaceuticals
June 23, 2020Manufacturing and Production, Sales and Marketing Boehringer, Hikma
Boehringer has revealed that it intends to withdraw its investment from Hikma Pharmaceuticals, with the company poised to sell 28 …
Boehringer’s TKI inhibitor Ofev gets FDA approval for chronic fibrosing interstitial lung diseases with a progressive phenotype
March 10, 2020Manufacturing and Production, Sales and Marketing Boehringer, FDA, ofev, pharma
The FDA has green-lit Boehringer Ingelheim’s multi-targeted tyrosine kinase inhibitor Ofev (nintedanib) in the treatment of chronic fibrosing interstitial lung …
Boehringer’s Pradaxa fails to meet Phase 3 endpoint in preventing recurrent stroke
May 20, 2019Research and Development, Sales and Marketing Boehringer, Pradaxa, pharma, stroke, trial failure
Boehringer has announced that Pradaxa (dabigatran etexilate mesylate) has failed to meet its primary endpoint in its Phase 3 study, …
Lilly and Boehringer’s Trajenta matches glimepiride in delaying cardiovascular events in type 2 diabetes patients
February 15, 2019Medical Communications, Research and Development Boehringer, Eli Lilly, cardiovascular disease, pharma, type 2 diabetes
Boehringer Ingelheim and Eli Lilly’s Trajenta (linagliptin) met its primary endpoint in a recent trial, it has emerged, proving itself …
Verona’s shares drop 34% on Phase 2 failure of nebulised ensifentrine in COPD
January 15, 2019Manufacturing and Production, Research and Development Boehringer, COPD, Stiolto Respimat, pharma, trial failure, verona pharma
Verona Pharma has seen its shares crater following the Phase 2 failure of its nebulised ensifentrine, known as RPL554, in …
Top Ten most popular articles on Pharmafile.com this week!
December 14, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Akorn, Boehringer, Novartis, Pfizer, Trump, UK, pharmafile, top 10
Business seemed to be the theme this week as Akorn’s acquisition of Fresenius fell through, while Boehringer announced a restructuring …
Boehringer’s France restructure will cull over 300 jobs
December 11, 2018Manufacturing and Production Boehringer, Sanofi, job cuts, pharma
Boehringer Ingelheim is set to follow in the recent steps of Sanofi with the announcement of a cull of over …
Boehringer signs $300 million deal with Epizyme over epigenetic cancer treatment
November 16, 2018Medical Communications Boehringer, Cancer, Epizyme, deal, oncology
German firm Boehringer Ingelheim and the Massachusetts-based biotech Epizyme have announced that they will collaborate on the development of novel, …
Boehringer teams up with OSE in €1.1 billion cancer drug partnership
April 5, 2018Sales and Marketing Boehringer, Cancer, OSE Immunotherapeutics, partnership, pharma
Boehringer Ingelheim and biotech firm OSE Immunotherapeutics have announced that they have entered an exclusive collaboration and license agreement to …
Top Ten most popular articles on Pharmafile.com this week
January 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Boehringer, CAR T, CAR-T, Celgene, Kymriah, Merck KGaA, Novartis, Philippines, Sanofi, gilotrif, juno therapeutics, nestle, top ten
It’s Friday, so it’s time to bring you another run-down of the top ten most popular articles with Pharmafile.com’s readers …
Boehringer loses CFO over financial strategy dispute
December 18, 2017Medical Communications, Sales and Marketing Boehringer, Boehringer Ingelheim, appointment, pharma
Boehringer Ingelheim is set to part ways with its Chief Financial Officer Simone Menne after 16 months due to fundamental …
Boehringer celebrates EU approval of Humira biosimilar
November 14, 2017Manufacturing and Production, Sales and Marketing Boehringer, Boehringer Ingelheim, Cyltezo, EU, Europe, European Commission, Humira, biosimilar
Boehringer Ingelheim has announced that Cyltezo, its biosimilar of Abbvie’s Humira, has received marketing authorisation approval from the European Commission, …
Five most talked about mergers and acquisitions of 2016
January 27, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actavis, Bayer, Boehringer, Johnson & Johnson, Sanofi, Teva, acquisition, mergers, monsanto, pharma
2017 has kicked off with a bang – as Johnson & Johnson confirmed a $30 billion deal to takeover of …
Pharma giants Sanofi and Boehringer negotiate deal to swap assets
December 15, 2015Business Services, Manufacturing and Production, Sales and Marketing Andreas Barner, Boehringer, Boehringer Ingelheim, Merial, Sanofi, olivier brandicourt
Two of the world’s biggest pharma companies – Sanofi and Boehringer Ingelheim – have entered into exclusive negotiations to swap …
